Target- |
MechanismIonising radiation emitters |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date03 May 2002 |
A Multicenter, Open-label, Single-Arm Phase I/II Clinical Study to Evaluate the Safety and Efficacy of a Single Dose of MDN-001 Injection in Patients With Unresectable Primary Hepatocellular Carcinoma (HCC).
The main purpose of the study is to evaluate the safety and efficacy of MDN-001 injection(Yttrium-90 Microsphere Injection)in the treatment of unresectable hepatocellular carcinoma. Other purposes of this study include assessment of the effect of treatment on overall survival, the length of time it takes for the disease to worsen, if and how the treatment affects the patient's quality of life, and if and how the cancer responds to the treatment.
/ Not yet recruitingPhase 1 一项评价 MDN-001 注射液单次给药治疗不可切除的原发性肝癌的安全性与有效性的多中心、开放、单臂 I/II 期临床研究
[Translation] A multicenter, open-label, single-arm Phase I/II clinical study to evaluate the safety and efficacy of a single dose of MDN-001 injection in the treatment of unresectable primary liver cancer
评价MDN-001注射液治疗不可切除的原发性肝癌的安全性与有效性。
[Translation] To evaluate the safety and efficacy of MDN-001 injection in the treatment of unresectable primary liver cancer.
100 Clinical Results associated with Suzhou Medinuoyi Medical Technology Co., Ltd.
0 Patents (Medical) associated with Suzhou Medinuoyi Medical Technology Co., Ltd.
100 Deals associated with Suzhou Medinuoyi Medical Technology Co., Ltd.
100 Translational Medicine associated with Suzhou Medinuoyi Medical Technology Co., Ltd.